Results 11 to 20 of about 14,806,844 (291)

National survey of pre-treatment HIV drug resistance in Cuban patients.

PLoS ONE, 2019
BACKGROUND:The World Health Organization (WHO) recommends a method to estimate nationally representative pretreatment HIV drug resistance (PDR) in order to evaluate the effectiveness of first -line treatments.
Liuber Y Machado, Madeline Blanco, Laura S López, Héctor M Díaz, Marta Dubed, Neisy Valdés, Enrique Noa, Liodelvio Martínez, María T Pérez, Dania M Romay, Caridad B Rivero, José Joanes, Isis Cancio, María I Lantero, Mireida Rodríguez   +14 more
doaj   +4 more sources

Pre-treatment and Acquired Antiretroviral Drug Resistance among People Living with HIV in Southwest China [PDF]

Zhongguo quanke yixue
Background The prevalence and epidemiology of pre-treatment drug resistance (PDR) and acquired drug resistance (ADR) among HIV-infected individuals vary considerably in different regions of China. Both types of drug resistance have adverse effects on the
KONG Linghong, XIE Xiaoxin, FU Yanhua, GAN Lin, YANG Xiaoyan, MA Shujing, LONG Hai
doaj   +2 more sources

Pre-treatment and acquired HIV drug resistance in Hunan: a cross-sectional analysis of a growing challenge

BMC Infectious Diseases
Background HIV Drug Resistance (HIVDR) is a key consideration when determining ART regimens. In recent years, Pre-treatment Drug Resistance (PDR) and Acquired Drug Resistance (ADR) have been changing rapidly.
Shujing Long, Run Yao, Yumei Tang, Chengcheng Yu, Wei Tang, Jing Cao, Yaxiong Huang, Xinlan Lu, Sai Li, Rangjiao Liu, Lizhong Dai, Yan Huang, Fang Zheng   +12 more
doaj   +4 more sources

Pre-treatment HIV drug resistance testing cost-effectiveness [PDF]

EClinicalMedicine, 2020
David AMC van de Vijver, Brooke E Nichols   +1 more
doaj   +3 more sources

Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.

PLoS ONE, 2016
BackgroundIn order to assess the level of transmitted and/or pre-treatment antiretroviral drug resistance to HIV-1, the World Health Organization (WHO) recommends that regular surveys are conducted.
Kim Steegen, Sergio Carmona, Michelle Bronze, Maria A Papathanasopoulos, Gert van Zyl, Dominique Goedhals, William MacLeod, Ian Sanne, Wendy S Stevens   +8 more
doaj   +5 more sources

Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon. [PDF]

PLoS One, 2020
With the scale-up of antiretroviral therapy (ART), pre-treatment drug resistance (PDR) appears ≥10% amongst ART-initiators in many developing countries, including Cameroon. Northwest region-Cameroon having the second epidemiological burden of HIV infection, generating data on PDR in these geographical settings, will enhance evidence-based decision ...
Fokam J, Takou D, Teto G, Nforbih SE, Kome OP, Santoro MM, Ngoufack ES, Eyongetah M, Palmer D, Fokunang ET, Fokunang CN, Colizzi V, Perno CF, Ndjolo A.   +13 more
europepmc   +7 more sources

Molecular transmission networks and pre-treatment drug resistance among individuals with acute HIV-1 infection in Baoding, China. [PDF]

PLoS One, 2021
BackgroundHuman immunodeficiency virus type 1 (HIV-1) genetic diversity and pre-treatment drug resistance (PDR) are major barriers to successful antiretroviral therapy (ART). In China, sexual intercourse is the most frequent route of HIV-1 transmission.
Shi P, Chen Z, Meng J, Su M, Yang X, Fan W, Shi H, Gao Y, Lu X.   +8 more
europepmc   +5 more sources

Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008-2010. [PDF]

BMC Res Notes, 2016
Zimbabwe set up 12 sentinel sites to monitor HIV drug resistance (HIVDR) following the international standards for prevention of HIVDR from 2008 to 2010.Participants were consecutively enrolled. Blood was collected and used for CD4 count, viral load (VL) and pre-treatment DR (PDR) tests besides routine baseline tests. We analyzed the characteristics of
Mungati M, Mhangara M, Gonese E, Mugurungi O, Dzangare J, Ngwende S, Musasa P, Wellington M, Shambira G, Apollo T, Yang C, DeVos J, Sabatier J, Kilmarx P, Chakanyuka-Musanhu C, Tshimanga M.   +15 more
europepmc   +4 more sources

A3 Brazilian network for HIV drug resistance surveillance: An investigation of pre-treatment drug resistance transmission chains [PDF]

Virus Evol, 2018
Véras N, Pires A, Tanuri A, Benzaken A.
europepmc   +3 more sources

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background [PDF]

, 2012
The evolution of drug-resistance in pathogens is a major global health threat. Elucidating the molecular basis of pathogen drug-resistance has been the focus of many studies but rarely is it known whether a drug-resistance mechanism identified is ...
Sylke Müller, Hideo Imamura (62469), Dujardin, J., Khanal, Basudha, Brunker, K., Brunker, Kirstyn, Kirstyn Brunker (181178), Graham H. Coombs (164011), Suman Rijal (181185), Imamura, Hideo, Jean-Claude Dujardin, M\ufcller, Sylke, Dujardin, Jean-Claude, Dujardin, J. C., Coombs, G. H., Muller, S., Jean-Claude Dujardin (56958), Decuypere, S., Coombs, G.H., Vanaerschot, M., Decuypere, Saskia, Coombs, Graham H, Rijal, S., Manu Vanaerschot, Sylke Müller (37476), Basudha Khanal, Khanal, B., Hideo Imamura, Kirstyn Brunker, Müller, Sylke, Coombs, Graham H., Vanaerschot, Manu, Imamura, H., Rijal, Suman, Saskia Decuypere, Basudha Khanal (181181), Saskia Decuypere (181176), Manu Vanaerschot (109210), Suman Rijal, Graham H Coombs   +39 more
core   +5 more sources